Apixaban in patients with atrial fibrillation

Cited by (1,002)

Items 101–200 of 1,002

1. 2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease
   Dharam J. Kumbhani, Christopher Paul Cannon, Craig James Beavers, Deepak L. Bhatt, Adam C. Cuker, Ty J. Gluckman, Joseph Edward Marine, Roxana Mehran, Steven Russell Messe, Nimesh S. Patel et al. · 2020 · Journal of the American College of Cardiology
2. Sex differences in cardiac arrhythmia: a consensus document of the European Heart Rhythm Association, endorsed by the Heart Rhythm Society and Asia Pacific Heart Rhythm Society
   Cecilia Marianne Linde, Maria Grazia Bongiorni, Ulrika Maria Birgersdotter-Green, Anne B. Curtis, Isabel Deisenhofer, Tetsushi Furokawa, Anne M. Gillis, Kristina Hermann Haugaa, Gregory Y.H. Lip, Isabelle C. Van Gelder et al. · 2018 · EP Europace
3. Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial
   Renato D. Lópes, Marco Alings, Stuart J. Connolly, Heather Beresh, Christopher Bull Granger, Juan Benezet Mazuecos, Giuseppe Boriani, Jens Cosedis Nielsen, David Conen, Stefan Hans Hohnloser et al. · 2017 · American Heart Journal
4. Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
   Mintu P. Turakhia, Peter J. Blankestijn, Juan Jesús Carrero, Catherine M. Clase, Rajat Deo, Charles A. Herzog, Scott Eric Kasner, ROD S. PASSMAN, Roberto Pecoits‐Filho, Holger Reinecke et al. · 2018 · European Heart Journal
5. Evaluating Real-World Clinical Outcomes in Atrial Fibrillation Patients Receiving the WATCHMAN Left Atrial Appendage Closure Technology
   Lucas V.A. Boersma, Hueseyin Ince, Stephan Kische, Evgeny Pokushalov, Thomas Schmitz, Boris Schmidt, Tommaso Gori, Felix Meincke, Alexey Vladimir Protopopov, Timothy R. Betts et al. · 2019 · Circulation Arrhythmia and Electrophysiology
6. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor<scp>X</scp>a inhibitor, in healthy subjects
   Frost, Charles, Nepal, Sunil, Wang, Jessie, Schuster, Alan, Byon, Wonkyung, Boyd, Rebecca A., Yu, Zhigang, Shenker, Andrew, Barrett, Yu Chen, Mosqueda‐Garcia, Rogelio et al. · 2013 · British Journal of Clinical Pharmacology
7. Indirect Comparisons of New Oral Anticoagulant Drugs for Efficacy and Safety When Used for Stroke Prevention in Atrial Fibrillation
   Gregory Y.H. Lip, Torben Bjerregaard Larsen, Flemming Skjøth, Lars Hvilsted Rasmussen · 2012 · Journal of the American College of Cardiology
8. Platelets and Their Role in Hemostasis and Thrombosis—From Physiology to Pathophysiology and Therapeutic Implications
   Alina Scridon · 2022 · International Journal of Molecular Sciences
9. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end‐stage renal disease on hemodialysis
   Xiaoli Wang, Giridhar Tirucherai, Thomas C Marbury, Jessie J.J. Wang, Ming Chang, Donglu Zhang, Yan Jun Song, Janice M. Pursley, Rebecca A. Boyd, Charles E. Frost · 2015 · The Journal of Clinical Pharmacology
10. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial
    J. Donald Easton, Renato D. Lópes, Maria Cecilia Bahit, DANIEL M. WOJDYLA, Christopher Bull Granger, Lars C. Wallentin, Marco Alings, Shinya Goto, Basil S. Lewis, Mårten Rosenqvist et al. · 2012 · The Lancet Neurology
11. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects
    Vijay V. Upreti, Jessie J.J. Wang, Yu Chen Barrett, Wonkyung Byon, Rebecca A. Boyd, Janice M. Pursley, Frank P. LaCreta, Charles E. Frost · 2013 · British Journal of Clinical Pharmacology
12. Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation
    Karen L. Furie, Larry B. Goldstein, Gregory W. Albers, Pooja Khatri, Ron R. Neyens, Mintu P. Turakhia, Tanya N. Turan, Kathryn Wood · 2012 · Stroke
13. Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study
    Leif Friberg, Lina Benson, Mina A. Rosenqvist, Gregory Y.H. Lip · 2012 · BMJ
14. New Oral Anticoagulants in Elderly Adults: Evidence from a Meta‐Analysis of Randomized Trials
    Partha Sardar, Saurav Chatterjee, Shobhana Chaudhari, Gregory Y.H. Lip · 2014 · Journal of the American Geriatrics Society
15. Restarting Anticoagulant Treatment After Intracranial Hemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality, and Bleeding: A Nationwide Cohort Study
    Nielsen, Peter Brønnum, Larsen, Torben Bjerregaard, Skjøth, Flemming, Gorst-Rasmussen, Anders, Rasmussen, Lars Hvilsted, Lip, Gregory Y.H. · 2015 · Circulation
16. New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes
    Raffaele De Caterina, Steen Husted, Lars C. Wallentin, Raffaele De Caterina, Steen Husted, Lars C. Wallentin, Felicita Andreotti, Harald Arnesen, F Bachmann, Colin Baigent et al. · 2012 · Journal of the American College of Cardiology
17. Hypertension and Atrial Fibrillation
    Paolo Verdecchia, Fabio Angeli, Gianpaolo Reboldi · 2018 · Circulation Research
18. Management of Patients on Non–Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association
    Amish N. Raval, Joaquin E. Cigarroa, Mina K. Chung, Larry J. Díaz‐Sandoval, Deborah Diercks, Jonathan Paul Piccini, Hee Soo Jung, Jeffrey B. Washam, Babu Guai Welch, Allyson R. Zazulia et al. · 2017 · Circulation
19. Direct Oral Anticoagulants for Stroke Prevention in Patients With Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials
    William F. McIntyre, Alexander Philipp Benz, Nina Becher, Jeff S. Healey, Christopher Bull Granger, Léna Rivard, A. John Camm, Andreas Goette, Antonia Zapf, Marco Alings et al. · 2023 · Circulation
20. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options—a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference
    Paulus F. Kirchhof, Gregory Y.H. Lip, Isabelle C. Van Gelder, Jeroen Joost Bax, Elaine M. Hylek, Stefan Kääb, Ulrich Schotten, Karl Wegscheider, Giuseppe Boriani, Axel Brandes et al. · 2011 · EP Europace
21. Sex Differences in Stroke Risk Among Older Patients With Recently Diagnosed Atrial Fibrillation
    Cynthia A. Jackevicius · 2012 · JAMA
22. The increasing impact of cerebral amyloid angiopathy: essential new insights for clinical practice
    Gargi Banerjee, Roxana Octavia Carare, Charlotte Cordonnier, Steven Mark Greenberg, Julie A. Schneider, Eric Edward Smith, Mark A. van Buchem, Jeroen van der Grond, Marcel M. Verbeek, David John Werring · 2017 · Journal of Neurology Neurosurgery & Psychiatry
23. Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis
    Felicita Andreotti, Bianca Rocca, Steen Husted, Ramzi Ajjan, Jurriën M. ten Berg, Marco Cattaneo, Jean‐Philippe Collet, Raffaele De Caterina, Keith A.A. Fox, Sigrun Halvorsen et al. · 2015 · European Heart Journal
24. Atrial fibrillation
    Gregory Y.H. Lip, Laurent Fauchier, Saul B. Freedman, Isabelle C. Van Gelder, Andrea Natale, Carola Gianni, Stanley Nattel, Tatjana Potpara, Michiel Rienstra, Hung‐Fat Tse et al. · 2016 · Nature Reviews Disease Primers
25. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD – Summary
    pre-diabetes Task Force on diabetes · 2014 · Diabetes and Vascular Disease Research
26. Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review
    Borre, Ethan, Goode, Adam, Raitz, Giselle, Shah, Bimal, Lowenstern, Angela, Chatterjee, Ranee, Sharan, Lauren, Allen LaPointe, Nancy, Yapa, Roshini, Davis, J. et al. · 2018 · Thrombosis and Haemostasis
27. Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non–vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH–AFNET 6) trial
    Paulus F. Kirchhof, Benjamin F. Blank, Melanie Calvert, A. John Camm, GREGORY I. CHLOUVERAKIS, Hans‐Christoph Diener, Andreas Goette, Andrea Huening, Gregory Y.H. Lip, EMMANUEL N. SIMANTIRAKIS et al. · 2017 · American Heart Journal
28. Pros and cons of new oral anticoagulants
    Kenneth Alan Bauer · 2013 · Hematology
29. 2020 Clinical guidelines for Atrial fibrillation and atrial flutter
    M. S. Arakelyan, Leo A. Bockeria, Elena Vasilieva, Golitsyn Sp, Elena Zelikovna Golukhova, M. V. Gorev, Karapet V. Davtyan, Oksana M. Drapkina, Кропачева Екатерина Станиславовна, Е. А. Kuchinskaya et al. · 2021 · Russian Journal of Cardiology
30. Hypertension and cardiac arrhythmias: a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE)
    Gregory Y.H. Lip, António Coca, Thomas Kahan, Giuseppe Boriani, Antonis S. Manolis, Michael Hecht Olsen, Ali̇ Oto, Tatjana Potpara, Jan Steffel, Francisco R. Marín et al. · 2017 · EP Europace
31. Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy
    Hooman Kamel, Will T. Longstreth, David Tirschwell, Richard A. Kronmal, Randolph S. Marshall, Joseph P. Broderick, Rebeca Aragón García, Pamela Plummer, Noor Sabagha, Qi Pauls et al. · 2024 · JAMA
32. Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study
    Peter L. Gross, Bruce C. Ritchie, Susan Nahirniak, Yulia Lin, Lani Lieberman, Marc Carrier, Mark Andrew Crowther, Indy Ghosh, Alejandro Lazo‐Langner, Michelle Zondag et al. · 2018 · Thrombosis and Haemostasis
33. International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries
    Benjamin Adam Steinberg, Haiyan Gao, Peter J. Shrader, Karen Pieper, Laine Elliott Thomas, A. John Camm, Michael D. Ezekowitz, Gregg C. Fonarow, Bernard John Gersh, Samuel Zachary Goldhaber et al. · 2017 · American Heart Journal
34. Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention
    Davide Capodanno, Roxana Mehran, Marco Valgimigli, Usman Baber, Stephan Windecker, Pascal Vranckx, George Dangas, Fabiana Rollini, Takeshi Kimura, Jean‐Philippe Collet et al. · 2018 · Nature Reviews Cardiology
35. Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial
    Jean‐Philippe Collet, Eric Van Belle, Hölger Thiele, Sérgio Luis Berti, Thibault Lhermusier, Thibault Manigold, Franz‐Josef Neumann, Martine Gilard, David Attias, Farzin Beygui et al. · 2022 · European Heart Journal
36. Early Safety and Efficacy of Percutaneous Left Atrial Appendage Suture Ligation
    Matthew J. Price, Douglas N Gibson, Steven Joseph Yakubov, Jason C. Schultz, Luigi Di Biase, Andrea Natale, J. David Burkhardt, Ashish Pershad, Timothy Byrne, Brett Gidney et al. · 2014 · Journal of the American College of Cardiology
37. Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline
    Catharina J.M. Klijn, Maurizio Paciaroni, Eivind Berge, Eleni Korompoki, Janika Kõrv, Avtar Lal, Jukka Putaala A, David John Werring · 2019 · European Stroke Journal
38. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial
    Renato D. Lópes, Sana M. Al‐Khatib, Lars C. Wallentin, Hongqiu Yang, Jack Ansell, Maria Cecilia Bahit, Raffaele De Caterina, Paul Dorian, J. Donald Easton, Çetin Erol et al. · 2012 · The Lancet
39. Rates of hemorrhage during warfarin therapy for atrial fibrillation
    Tara Gomes, Muhammad Mamdani, Anne Marie Holbrook, John Michael Paterson, Chelsea Hellings, David Nelson Juurlink · 2012 · Canadian Medical Association Journal
40. Meta-analysis of gender differences in residual stroke risk and major bleeding in patients with nonvalvular atrial fibrillation treated with oral anticoagulants
    Pancholy, Samir B., Sharma, Parikshit S., Pancholy, Dipti S., Patel, Tejas M., Callans, David J., Marchlinski, Francis E. · 2014 · The American Journal of Cardiology
41. Warfarin in atrial fibrillation patients with moderate chronic kidney disease
    Hart, Robert G., Pearce, Lesly A., Asinger, Richard W., Herzog, Charles A. · 2011 · Clinical Journal of the American Society of Nephrology
42. Consensus Document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting
    John W. Eikelboom, Peter B. Berger, David R. Holmes, Deepak L. Bhatt, Richard Clinton Becker, Dominick Angiolill, David P. Faxon, David J. Moliterno · 2011 · Thrombosis and Haemostasis
43. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy
    Stefan Agewall, Marco Cattaneo, J.‐P. Collet, Felicita Andreotti, Gregory Y.H. Lip, Freek W.A. Verheugt, Kurt Huber, Erik Lerkevang Grove, João Morais, Steen Husted et al. · 2013 · European Heart Journal
44. Unexpectedly High Incidence of Stroke and Left Atrial Appendage Thrombus Formation After Electrical Isolation of the Left Atrial Appendage for the Treatment of Atrial Tachyarrhythmias
    Andreas Rillig, Roland Richard Tilz, Tina Lin, Thomas Fink, Christian-Hendrik H. Heeger, Anita Arya, Andreas Metzner, Shibu Mathew, Erik Wißner, Hisaki Makimoto et al. · 2016 · Circulation Arrhythmia and Electrophysiology
45. Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms
    Francesco Violi, Elsayed Z. Soliman, Pasquale Pignatelli, Daniele Pastori · 2016 · Journal of the American Heart Association
46. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis
    Jonathan A C Sterne, Pritesh N. Bodalia, Peter A. Bryden, Philippa A. Davies, José A López-López, George N. Okoli, Howard H. Z. Thom, Deborah M Caldwell, Sofia Dias, Diane Eaton et al. · 2017 · Health Technology Assessment
47. Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group ‘Hypertension Arrhythmias and Thrombosis’ of the European Society of Hypertension
    Manolis, Athanasios J., Rosei, Enrico Agabiti, Coca, Antonio, Cifkova, Renata, Erdine, Serap E., Kjeldsen, Sverre, Lip, Gregory Y.H., Narkiewicz, Krzysztof, Parati, Gianfranco, Redon, Josep et al. · 2012 · Journal of Hypertension
48. Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial
    Breithardt, Günter, Baumgartner, Helmut, Berkowitz, Scott D., Hellkamp, Anne S., Piccini, Jonathan P., Stevens, Susanna R., Lokhnygina, Yuliya, Patel, Manesh R., Halperin, Jonathan L., Singer, Daniel E. et al. · 2014 · European Heart Journal
49. Cryptogenic Stroke
    Shadi R. Yaghi, Richard A. Bernstein, ROD S. PASSMAN, Peter M. Okin, Karen L. Furie · 2017 · Circulation Research
50. Overview of the New Oral Anticoagulants
    Calvin H. Yeh, Kerstin E. Hogg, Jeffrey Ian Weitz · 2015 · Arteriosclerosis Thrombosis and Vascular Biology
51. 2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation
    Chern‐En Chiang, Ken Okumura, Shu Zhang, Tze‐Fan Chao, Chung‐Wah Siu, Toon Wei Lim, Anil Saxena, Yoshihide Takahashi, Wee Siong Teo · 2017 · Journal of Arrhythmia
52. Direct oral anticoagulants: evidence and unresolved issues
    Noel Chan, Magdalena Sobieraj‐Teague, John W. Eikelboom · 2020 · The Lancet
53. Bioprosthetic Valve Thrombosis
    Rishi Puri, Vincent Auffret, Josep Rodés‐Cabau · 2017 · Journal of the American College of Cardiology
54. Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups
    Antonio Gómez‐Outes, Ana Isabel Terleira‐Fernández, Gonzalo Calvo, Ma Luisa Suárez‐Gea, Emilio Vargas · 2013 · Thrombosis
55. Medical treatment in acute and long-term secondary prevention after transient ischaemic attack and ischaemic stroke
    Peter Malcolm Rothwell, Ale Algra, Pierre Amarenco · 2011 · The Lancet
56. New Oral Anticoagulants and the Risk of Intracranial Hemorrhage
    Saurav Chatterjee, Partha Sardar, Giuseppe Biondi‐Zoccai, Dharam J. Kumbhani · 2013 · JAMA Neurology
57. The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy
    Michiel Coppens, John W. Eikelboom, Robert G. Hart, Salim Yusuf, Gregory Y.H. Lip, Paul Dorian, Olga Shestakovska, Stuart J. Connolly · 2012 · European Heart Journal
58. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban
    Thorsten Steiner, Michael Böhm, Martin Dichgans, HC Diener, Christian Ell, Matthias Endres, Corina Epple, Martin Grond, Ulrich Laufs, Georg Nickenig et al. · 2013 · Clinical Research in Cardiology
59. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial
    Jeroen Jaspers Focks, Marc A. Brouwer, DANIEL M. WOJDYLA, Laine Elliott Thomas, Renato D. Lópes, Jeffrey B. Washam, Fernando Tomas Lanas, Denis Xavier, Steen Husted, Lars C. Wallentin et al. · 2016 · BMJ
60. General mechanisms of coagulation and targets of anticoagulants (Section I)
    Steen Husted, Lars C. Wallentin, Felicita Andreotti, Harald Arnesen, F Bachmann, Colin Baigent, Kurt Huber, Jørgen Jespersen, Steen Dalby Kristensen, Gregory Y.H. Lip et al. · 2013 · Thrombosis and Haemostasis
61. Adherence to oral anticoagulant therapy in patients with atrial fibrillation
    Valeria Raparelli, Marco Proietti, Roberto Cangemi, Gregory Y.H. Lip, Deirdre A. Lane, Stefania Basili · 2016 · Thrombosis and Haemostasis
62. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial
    Diener, Hans-Christoph, Eikelboom, John, Connolly, Stuart J, Joyner, Campbell D, Hart, Robert G, Lip, Gregory YH, O'Donnell, Martin, Hohnloser, Stefan H, Hankey, Graeme J, Shestakovska, Olga et al. · 2012 · The Lancet Neurology
63. Atrial Cardiopathy: A Broadened Concept of Left Atrial Thromboembolism Beyond Atrial Fibrillation
    Hooman Kamel, Peter M. Okin, W. T. Longstreth, Mitchell S.V. Elkind, Elsayed Z. Soliman · 2015 · Future Cardiology
64. Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis
    Armando Tripodi, Massimo Primignani, Laura Lemma, Veena Chantarangkul, Pier Mannuccio Mannucci · 2013 · Journal of Hepatology
65. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban
    Ming Chang, Zhigang Yu, Andrew Shenker, Jessie J.J. Wang, Janice M. Pursley, Wonkyung Byon, Rebecca A. Boyd, Frank P. LaCreta, Charles E. Frost · 2015 · The Journal of Clinical Pharmacology
66. Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI
    Davide Capodanno, Kurt Huber, Roxana Mehran, Gregory Y.H. Lip, David P. Faxon, Christopher Bull Granger, Pascal Vranckx, Renato D. Lópes, Gilles Montalescot, Christopher Paul Cannon et al. · 2019 · Journal of the American College of Cardiology
67. Managing New Oral Anticoagulants in the Perioperative and Intensive Care Unit Setting
    Jerrold H. Levy, David Faraoni, Jenna L. Spring, James Demetrios Douketis, Charles Marc Samama · 2013 · Anesthesiology
68. Acute management of bleeding in patients on novel oral anticoagulants
    Deborah M. Siegal, Mark Andrew Crowther · 2012 · European Heart Journal
69. What is ‘valvular’ atrial fibrillation? A reappraisal
    Raffaele De Caterina, A. John Camm · 2014 · European Heart Journal
70. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naive atrial fibrillation patients: Danish nationwide descriptive data 2011-2013
    Jonas Bjerring Olesen, Rikke Sørensen, Morten Lock Hansen, Morten Lamberts, Peter Ejvin Weeke, Anders Pretzmann Mikkelsen, Lars Køber, Gunnar Gislason, Christian Tobias Torp-Pedersen, Emil Loldrup Fosbøl · 2014 · EP Europace
71. Social determinants of atrial fibrillation
    Utibe R. Essien, Jelena Kornej, Amber E. Johnson, Lucy Schulson, Emelia J. Benjamin, Jared W. Magnani · 2021 · Nature Reviews Cardiology
72. Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study design
    Tobias Geisler, Sven Poli, Christoph Meisner, Jüergen Schreieck, Christine S. Zuern, Thomas Nägele, Johannes Brachmann, Werner Jung, Georg Gahn, Elisabeth Verena Schmid et al. · 2016 · International Journal of Stroke
73. Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications (Second Edition)
    Samer Narouze, Honorio T. Benzon, David Anthony Provenzano, Asokumar Buvanendran, José Antonio De Andrés, Timothy Ray Deer, Richard L Rauck, Marc Alan Huntoon · 2017 · Regional Anesthesia & Pain Medicine
74. Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation
    Victoria Jacobs, Heidi Thomas May, Tami L. Bair, Brian G. Crandall, Michael J. Cutler, John D. Day, Charles D. Mallender, Jeffrey S. Osborn, Scott M. Stevens, J. Peter Weiss et al. · 2016 · The American Journal of Cardiology
75. Stroke and Thromboembolism in Atrial Fibrillation
    Ron Pisters, Deirdre A. Lane, Francisco R. Marín, A. John Camm, Gregory Y.H. Lip · 2012 · Circulation Journal
76. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score
    Lip, Gregory Y.H., Skjøth, Flemming, Rasmussen, Lars Hvilsted, Larsen, Torben Bjerregaard · 2015 · Journal of the American College of Cardiology
77. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor X a inhibitor
    Charles E. Frost, Wonkyung Byon, Yan Jun Song, Jessie J.J. Wang, Alan E. Schuster, Rebecca A. Boyd, Donglu Zhang, Zhigang Yu, Clapton S. Dias, Andrew Shenker et al. · 2014 · British Journal of Clinical Pharmacology
78. Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why?
    Gregory Y.H. Lip · 2012 · European Heart Journal
79. Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation.
    Luciano Crippa, Anna Falanga, Guido Finazzi, Francesco Marongiu, Gualtiero Palareti, Daniela Poli, Sophie Testa, Eros Tiraferri, Alberto Tosetto, Armando Tripodi et al. · 2011 · Thrombosis and Haemostasis
80. Improving outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial
    Kirchhof, Paulus, Breithardt, Günter, Camm, A. John, Crijns, Harry J., Kuck, Karl-Heinz, Vardas, Panos, Wegscheider, Karl · 2013 · American Heart Journal
81. Effect of Activated Charcoal on Apixaban Pharmacokinetics in Healthy Subjects
    Xiaoli Wang, Sabiha A. Mondal, Jessie J.J. Wang, Giridhar Tirucherai, Donglu Zhang, Rebecca A. Boyd, Charles E. Frost · 2013 · American Journal of Cardiovascular Drugs
82. Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation
    Danielle Clarkesmith, Helen M. Pattison, Phyo Khaing, Deirdre A. Lane · 2017 · Cochrane Database of Systematic Reviews
83. Reversal of anticoagulants: an overview of current developments
    Thomas Thiele, Kathleen Selleng, Andreas Greinacher · 2015 · Thrombosis and Haemostasis
84. Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: A global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation
    Menno Volkert Huisman, Gregory Y.H. Lip, Hans‐Christoph Diener, Sérgio Dubner, Jonathan L. Halperin, Shang‐Hung Chang, Kenneth Jay Rothman, Christine Teutsch, Kristina Zint, Diana Ackermann et al. · 2013 · American Heart Journal
85. Adverse Drug Events as a Cause of Hospitalization in Older Adults
    Fabio Salvi, Annalisa Marchetti, Federica D’Angelo, Massimo Boemi, Fabrizia Lattanzio, Antonio Cherubini · 2012 · Drug Safety
86. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1
    Hans‐Christoph Diener, James Aisenberg, Jack Ansell, Dan Atar, GÜNTER E. BREITHARDT, John W. Eikelboom, Michael D. Ezekowitz, Christopher Bull Granger, Jonathan L. Halperin, Stefan Hans Hohnloser et al. · 2016 · European Heart Journal
87. The Global Burden of Atrial Fibrillation and Stroke
    Ying Bai, Yanliang Wang, Alena Shantsila, Gregory Y.H. Lip · 2017 · CHEST Journal
88. An enhanced ResNet-50 deep learning model for arrhythmia detection using electrocardiogram biomedical indicators
    R. Anand, S. Vijaya Lakshmi, Digvijay Pandey, Binay Kumar Pandey · 2023 · Evolving Systems
89. Outcomes registry for better informed treatment of atrial fibrillation: Rationale and design of ORBIT-AF
    Jonathan Paul Piccini, Elizabeth S. Fraulo, Jack Ansell, Gregg C. Fonarow, Bernard John Gersh, Alan S. Go, Elaine M. Hylek, Peter Russell Kowey, Kenneth W. Mahaffey, Laine Elliott Thomas et al. · 2011 · American Heart Journal
90. Drug persistence with rivaroxaban therapy in atrial fibrillation patients--results from the Dresden non-interventional oral anticoagulation registry
    J. Beyer-Westendorf, K. Förster, Franziska Ebertz, Vera Gelbricht, T. Schreier, M. Gobelt, Franziska Michalski, Heike Endig, Kurtuluş Şahin, Luise Tittl et al. · 2015 · EP Europace
91. Atrial Fibrillation and Thromboembolism in Patients With Chronic Kidney Disease
    Yee Cheng Lau, Marco Proietti, Elisa Guiducci, Andrew D. Blann, Gregory Y.H. Lip · 2016 · Journal of the American College of Cardiology
92. Rationale and design of the Left Atrial Appendage Occlusion Study (LAAOS) III.
    Richard Paul Whitlock, Jeff S. Healey, Jessica Vincent, Kate Brady, Kevin Teoh, Alistair George Royse, Pallav J. Shah, Yingqiang Guo, Marco Alings, Richard Folkeringa et al. · 2014 · Europe PMC (PubMed Central)
93. Net Clinical Benefit of Adding Clopidogrel to Aspirin Therapy in Patients With Atrial Fibrillation for Whom Vitamin K Antagonists Are Unsuitable
    Stuart J. Connolly, John W. Eikelboom, Jennifer Ng, Jack Hirsh, Salim Yusuf, Janice Pogue, Raffaele de Caterina, Stefan Hohnloser, Robert G. Hart · 2011 · Annals of Internal Medicine
94. 2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation
    Chern‐En Chiang, Tsu-Juey Wu, Kwo-Chang Ueng, Tze‐Fan Chao, Kuan‐Cheng Chang, Chun-Chieh Wang, Yenn‐Jiang Lin, Wei‐Hsian Yin, Jen‐Yuan Kuo, Wei‐Shiang Lin et al. · 2016 · Journal of the Formosan Medical Association
95. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE)
    Gregory Y.H. Lip, Jean‐Philippe Collet, Raffaele De Caterina, Laurent Fauchier, Deirdre A. Lane, Torben Bjerregaard Larsen, Francisco R. Marín, João Morais, Calambur Narasimhan, Brian Olshansky et al. · 2017 · EP Europace
96. Assessment of a Machine Learning Model Applied to Harmonized Electronic Health Record Data for the Prediction of Incident Atrial Fibrillation
    Premanand Tiwari, Kathryn L. Colborn, Derek E. Smith, Fuyong Xing, Debashis Ghosh, Michael A. Rosenberg · 2020 · JAMA Network Open
97. Risk of Gastrointestinal Bleeding in Patients Taking Non–Vitamin K Antagonist Oral Anticoagulants: A Systematic Review and Meta-analysis
    Corey Miller, Alastair P. Dorreen, Myriam Martel, Thao Thanh Huynh, Alan N. Barkun · 2017 · Clinical Gastroenterology and Hepatology
98. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention
    John Hunter Alexander, DANIEL M. WOJDYLA, Amit N. Vora, Laine Elliott Thomas, Christopher Bull Granger, Shaun G. Goodman, RONALD S. ARONSON, Stephan Windecker, Roxana Mehran, Renato D. Lópes · 2020 · Circulation
99. Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs
    Freek W.A. Verheugt, Christopher Bull Granger · 2015 · The Lancet
100. 2014 Chinese guidelines for secondary prevention of ischemic stroke and transient ischemic attack
     Yongjun Wang, Ming Liu, Chuanqiang Pu · 2017 · International Journal of Stroke